It has been clearly demonstrated that the IL28B SNPs are strongly predictive of SVR to PR therapy in patients infected by HCV genotype 1,10–13 and accordingly to some authors they may be useful in other genotypes,30–32 thus we did not limit the analysis to HCV genotype 1 infection. This evidence concerns the gene IFNL3 and infection.